C-5EF1targeted calcification reversal, elastin targeting, bioengineering
0-100 chain-logic scale · 15 dimensions · scored on public evidence
%PDF-1.7 %���� 509 0 obj > endobj xref 509 27 0000000016 00000 n 0000002018 00000 n 0000002168 00000 n 0000003200 00000 n 0000003778 00000 n 0000003815 00000 n 0000003927 00000 n 0000004184 00000 n 0000004827 00000 n 0000005249 00000 n 0000005363 00000 n 0000005827 00000 n 0000006089 00000 n 0000006625 00000 n 0000007162 00000 n 0000007417 00000 n 0000008008 00000 n 0000010658 00000 n 0000023309 00000 n 0000033788 00000 n 0000045268 00000 n 0000045394 00000 n 0000051034 00000 n 0000051073 00000 n 0000051148 00000 n 0000057823 00000 n 0000000836 00000 n trailer ]/Prev 8708729>> startxref 0 %%EO … -ac5660fdb530 xmp.did:E0EAC20CB1BCE511889DDE5F03167222 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 2014 (Windows) / 2017-01-12T18:49:18+01:00 saved xmp.iid:2322c236-896a-ab4c-987f-e5512f89dff5 2017-05-03T11:58:21-07:00 Adobe Illustrator CC 2017 (Windows) / application/pdf report_cover Adobe PDF library 15.00 False 1 True False 630.000000 810.000000 Pixels Cyan Magenta Yellow Black Default Swatch Group 0 R=0 G=0 B=0 1 CMYK PROCESS 74.60 … �@.�P�� endstream endobj 40 0 obj > endobj 41 0 obj > endobj 42 0 obj >stream application/pdf SecondHeartAssist 2017-09-19T09:33:28-07:00 2017-09-19T09:33:28-07:00 2017-09-19T09:33:28-07:00 Adobe Illustrator CC 2017 (Macintosh) uuid:718c829a-7c72-ab44-9e8b-9cf657ea3493 xmp.did:5e11ef6a-d929-4577-a684-2a4e47ef94c8 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:6afcc52a-bdfa-4ed8-b9dc-8b4a8c56f577 xmp.did:6afcc52a-bdfa-4ed8-b9dc-8b4a8c56f577 uuid:5D20892493BFDB11914A … I���8ѻ�"j ��*3z�f���ې��ي��%� uq$��t�_JoG8�L�Ғ-MS8���VZ�K\MƄ�v ؠ >stream application/pdf PressureStimLogo 2018-08-22T08:11:01-07:00 2018-08-22T08:11:01-07:00 2018-08-22T08:11:01-07:00 Adobe Illustrator CC 22.1 (Macintosh) uuid:daf8abf4-c69c-2045-a87a-f6f92fe10dfc xmp.did:69d56c60-df9d-4a0a-98c9-5abb4475cfb1 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:ea21a5d1-41ba-c94c-8298-2927bba056c5 xmp.did:2ebf3a29-49fe-4402-8e5d-b3a48519ef32 uuid:5D20892493BFDB11914A8590 … 100 Adobe PDF library 15.00 endstream endobj 59 0 obj > endobj 60 0 obj >stream application/pdf BioLeonhardt 2017-09-19T10:13:20-07:00 2017-09-19T10:13:20-07:00 2017-09-19T10:13:20-07:00 Adobe Illustrator CC 2017 (Macintosh) uuid:db058cf9-a8c1-ba48-bb2a-0093302da3c6 xmp.did:d5315bb0-7f3a-49ae-af08-75278d055ef0 uuid:5D20892493BFDB11914A8590D31508C
#resiboston2024 #lifesciences #investmentopportunities #nih #healthcareinnovation #nondilutivefunding #sbir #sttr | Todd Rubinstein | 10 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cl
Elastrin Therapeutics-VCBeat VCBeat Health Contact Us Home China Healthcare Select Insights MNC China Lens Vertical Industries Services Partnership Development Market Entry Advisory Ecosystem Engagement Advisory About VCBeat Why VCBeat Log In Home Elastrin Therapeutics Elastrin Therapeutics In operation - Biopharmaceutical R&D for Cardiovascular Disease Treatment Basic Information Elastrin Therapeutics is a South Carolina-based biotechnology company developing new treatments to reverse cardiovascular disease. Its foundational technology was co-developed by Dr. Naren Vyavahare over th
Dein Browser wird nicht mehr unterstützt. Bitte führe ein Upgrade durch. YouTube Music ist nicht für deinen Browser optimiert. Suche nach Updates oder teste Google Chrome. Chrome herunterladen
On the back of a successful $9.8 million capital raise, PI CEO Stuart Elliott spoke to ticker about the future of healthtech innovation and regulated healthcare manufacturing after COVID. | Planet Innovation
GelSana Therapeutics - aVenture Company Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data
%PDF-1.4 %���� 8467 0 obj > endobj xref 8467 180 0000000016 00000 n 0000007535 00000 n 0000007721 00000 n 0000012727 00000 n 0000013292 00000 n 0000013853 00000 n 0000013933 00000 n 0000014048 00000 n 0000014581 00000 n 0000015200 00000 n 0000015313 00000 n 0000015403 00000 n 0000015994 00000 n 0000016631 00000 n 0000016730 00000 n 0000016898 00000 n 0000020671 00000 n 0000025976 00000 n 0000031347 00000 n 0000036237 00000 n 0000036362 00000 n 0000036487 00000 n 0000036613 00000 n 0000036738 00000 n 0000036853 00000 n 0000041502 00000 n 0000041773 00000 n 0000042033 00000 n 0000042333 00000 n … 8511 0 obj > endobj 8512 0 obj > endobj 8513 0 obj > endobj 8514 0 obj >stream application/pdf RESI Full 2022-08-30T13:23:11-04:00 2022-08-30T13:23:11-04:00 2022-08-30T13:23:10-04:00 Adobe Illustrator 26.3 (Windows) uuid:166d2bf4-d4d5-4dba-af2c-9687b1393474 xmp.did:b8b627b9-63dc-f348-9625-1ed948e71f30 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:40f0d353-75a6-694e-b6ea-5f797d1823ba xmp.did:40f0d353-75a6-694e-b6ea-5f797d1823ba uuid:5D20892493BFDB11914A8590D31508C8 … Adobe PDF library 16.07 endstream endobj 8515 0 obj > endobj 8516 0 obj >stream application/pdf RESI Global 2022-08-30T12:44-04:00 2022-08-30T12:44-04:00 2022-08-30T12:43:59-04:00 Adobe Illustrator 26.3 (Windows) uuid:bf1c6c4b-8c94-4f4f-9641-634d66e081c8 xmp.did:40f0d353-75a6-694e-b6ea-5f797d1823ba uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590D31508C8 proof:p … Adobe PDF library 16.07 endstream endobj 8517 0 obj > endobj 8518 0 obj >stream application/pdf LSN Logo 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 Adobe Illustrator 26.3 (Windows) uuid:4f5ba327-632d-4d3e-9750-3dbb5ac53375 xmp.did:08a59ab9-3855-0341-99ff-96f16744b3b7 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:b8b627b9-63dc-f348-9625-1ed948e71f30 xmp.did:b8b627b9-63dc-f348-9625-1ed948e71f30 uuid:5D20892493BFDB11914A8590D31508C8 d … Adobe PDF library 16.07 endstream endobj 8519 0 obj > endobj 8520 0 obj >stream application/pdf Eli lilly Logo 2022-08-30T13:41:59-04:00 2022-08-30T13:41:59-04:00 2022-08-30T13:41:59-04:00 Adobe Illustrator 26.3 (Windows) uuid:3f28006f-8ff8-45eb-9aae-4be6f7eceea3 xmp.did:361a8268-9583-8a4f-92ab-b9350d09be3d uuid:5D20892493BFDB11914A8590D31508C8 p
Biotech Strategy Workshop | RESI London 2025 Skip to main content Hit enter to search or ESC to close Close Search Solutions Solutions Transform your drug development journey with Certara’s comprehensive solutions. From molecule to market, we seamlessly integrate science, technology, strategic and regulatory expertise to solve your unique challenges. Discover more Regulatory Navigate complex regulatory landscapes with tailored strategies and AI-driven tools. Model-Informed Drug Development (MIDD) Reduce development risk and accelerate decisions using predictive science and model-informed strat … pitfalls often lead to costly delays, investor hesitation, or program failure. Submit your request to register What you’ll gain by attending: Investor perspective: Hear directly from investors and industry leaders about current trends, common pitfalls, and what they look for when funding early-stage biotech. Smarter candidate selection: Learn how to evaluate therapeutic potential and choose the right clinical candidate to advance with confidence. De-risked development planni … . He also leads projects focusing on managed markets communications strategies. Submit your request to register You May Also Like PBPK Modelling of Bispecific Monoclonal Antibody Tumour Targeting Specificity PBPK Modelling of Bispecific Monoclonal Antibody Tumour Targeting Specificity Poster PBPK Modelling of Bispecific Monoclonal Antibody Tumour Targeting Specificity Sex-Specific Bioequivalence Outcomes: PBPK Insights into Gastric Emptying Variability Sex-Specific Bioequival
Lifeboat Foundation | Proud to lead this $10M round at Kizoo portfolio company Elastrin Therapeutics Inc
--> Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round | Corporate - EQS News News Feed Events Feed News + Events Feed Recently viewed news Recently viewed events Show all --> Recently viewed Companies Search Results of news Show all Search Results of Companies Show all Search Results of events Show all Watch list Log in Log in E-mail Address Password Remember Me Log in Forgot Password You have not yet registered? Get your account for free. Register Here Back to log in Forgot Password? We will send you a reset link E-mail Reset Password News Feed My Watchlists News La … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others. Forever Healthy’s other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging, and hosting the annual Undoing Aging Conference. For more inf
Frontiers | Rheumatic heart valve disease: navigating the challenges of an overlooked autoimmune disorder Frontiers in Cardiovascular Medicine About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee policy Services Societies National consortia Institutional partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Caree … office Sustainability Career opportunities Contact us All journals All articles Submit your research Search Frontiers in Cardiovascular Medicine Sections Sections Aortic Surgery and Endovascular Repair Archive Atherosclerosis and Vascular Medicine Cardiac Rhythmology Cardio-Oncology Cardioneurology Cardiovascular Biologics and Regenerative Medicine Cardiovascular Epidemiology and Prevention Cardiovascular Genetics and Systems Medicine Cardiovascular Imaging Cardiovascular Met … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee p … partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Career opportunities Contact us All journals All articles Submit your research Frontiers in Cardiovascular Medicine Sections Sections Aortic Surgery and Endovascular Repair Archive Atherosclerosis and Vascular Medicine Cardiac Rhythmology Cardio-Oncology Cardioneurology Cardiovascular Biologics and Regenerative Medicine Cardiovascular Epidemiology and Prevention C … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office Frontiers in Cardiovascular Medicine Sections Sections Aortic Surgery and Endovascular Repair Archive Atherosclerosis and Vascular Medicine Cardiac
Digital RESI March 2023 – RESI Conference Skip to content Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs Program Guides Photo Albums Registration RESI San Diego (June) RESI Boston (Sept) Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs … administers MABA’s internal investment pools, and MABA’s co-investment Sidecar Fund for non MABA member investors. Mr. Sneor is also Chief Executive Officer of Native State Therapeutics, an early stage biotechnology company in the neurodegeneration field, and President of Blue Cactus Consulting a business strategy consulting group. Yaniv Sneor is originally a physicist, who made the transition into the business world about 30 years ago, at which point he took the helm of his … ity and an MBA from Harvard Business School. Krish Ramadurai, Partner, Harmonix Fund Mr. Krish Ramadurai serves as a Partner at Harmonix. At Harmonix, he leads the firm’s due diligence, sourcing, and portfolio operational support. He serves as a Board Observer at Sorcero and xCures. He is a multi-published author and former researcher that has held previous appointments at Harvard University’s Belfer Center for Science and International Affairs, the Taubman Center for State a … llinois at Urbana-Champaign. Joseph Mocanu, Managing Partner, Verge Health Tech Fund Joseph started his career as a scientist, developing new cancer therapies during his PhD at the University of Toronto. He co-founded a medical device startup during his studies which brought him into the world of business and his first interactions with VCs. He first learned about active investing during his time at DM Capital in Shenzhen, helping launch their first fund, Harmony. He then joi … ior to joining ACS/BrightEdge, Steve managed MPM Capital’s Oncology Innovations Fund, a hybrid venture/philanthropy investment collaboration with Dana-Farber Cancer Institute. At MPM, he led the investments in seed and Series A stage biotech companies and held various interim operating roles in many of these start-ups. Steve also supported MPM’s
#technology #rejuvenationstartupsummit #biotech #rejuvenation #longevity #elastinrepair #elastrin | Elastrin Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Venture Kick - Immitra Bio receives CHF 150,000 from... Facebook Log In Venture Kick's Post Venture Kick June 15 at 6:03 AM · Shared with Public Immitra Bio receives CHF 150,000 from Venture Kick to reimagine stem cell therapy for rare diseases The ETH Zürich spin off Immitra Bio has secured CHF 150,000 in Venture Kick Stage III funding to develop a new treatment approach for rare genetic diseases. The company is developing an in vivo stem cell therapy platform that aims to replace complex transplants with a single off-the-shelf treatment, initially targeting severe inherited red blood ce
News - SCRA: South Carolina Research Authority Search for: SCRA Membership Menu Get to know SCRA Who We Are Mission Our Boards Board of Trustees Meeting Schedules S&T Meeting Schedule Document Center Our Team Working at SCRA Our Strategic Initiatives What We Do Center for Cybersecurity Center for Research Security Innovation Hubs Our Sustainability Our Impact Get Support SCRA Membership Grant Funding Tech Catalyst Fund Connect to Resources SCRA Member Benefits SCRA’s Startup Resources SCRA Webinars Podcasts Tech Startup Lifecycle Series Thought Leadership Series Solve Industry Needs Get R … Series Thought Leadership Series Solve Industry Needs Get Research Funding SACT Grant Establish South Carolina Location Lease Space Give Support Industry Partnership Fund IPF Newsletter SCRA’s Startup Resources Stay Connected News Media Kit Newsletter Social Freedom of Information Act SC Launch Who We Are Criteria and Eligibility Our Portfolio SCRA Membership SCRA Membership SCRA News Keep up with the latest news from SCRA and news from across the state. Featured Article SCRA … s from SCRA and news from across the state. Featured Article SCRA announces new grant funding, academic funding, and member companies Columbia, S.C. – Volare Boats, Cuffway, SusMaTech, Memberworks, and PSF R&D Labs received new grant funding from the South Carolina Research Authority. Clemson University received new academic grant funding. LivIQ Health, Land Takeoffs, Oral Pouch Solutions, and Petra Loan Servicing were accepted as SCRA member companies. SCRA President and … said, “We welcome these […] Read more News News Releases America’s Seed Fund renewal good news for SC small businesses South Carolina’s small business innovation community received a major piece of good news this spring: Congress has reauthorized the Small Business Innovation Research and Small Business Technology Transfer programs, ending a long period of uncertainty stalling one of the federal government’s most powerful tools for fueling small business growth. For S … y startups focused on improving rural health access. The program, Tech Catalyst Fund, is one of five initiatives within South Carolina’s Rural Health Transformation Program, administered by the Centers for Medicare & Medicaid Services and the South Carolina Department of Health and Human Services. SCDHHS has contracted […] SCRA a
--> Antibody-Targeted Nanoparticle Therapy | Flexibzumab, Elastrin top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Continue Reading The Elastrin Platform Elastrin uses antibody-guided nanoparticles as a biological navigation system. Each particle is programmed to seek damaged elastin and deliver therapy exactly where calcification begins. Continue Reading Enabler Therapy Calcification blocks the procedures that could save patients. Elastrin Clears the Path. Many device interventions for vascular disease cannot be performed when vessel wall … hysicians, and Partners A defined pathway from preclinical evidence to clinical application. Surgical and device interventions for vascular disease are frequently prevented or compromised by the very calcification they are meant to treat. When vessels are too stiff, procedures cannot be performed , leaving patients with no option but radical surgery or, in the case of peripheral artery disease, amputation. Elastrin's approach addresses this
%PDF-1.7 %���� 1116 0 obj > endobj 1150 0 obj >/Filter/FlateDecode/ID[ ]/Index[1116 53]/Info 1115 0 R/Length 140/Prev 556419/Root 1117 0 R/Size 1169/Type/XRef/W[1 3 1]>>stream h�bbd```b`�b� �A$�F��"�o�H�D0�L���z0�I�>h)�f/�Y �� D2f��`�u�] "�����`]L`2H2���̋ YTA�[�.F 0��ߓ� L� ,��~a`�!���߹ >stream hޜVkTW �3� I ��h H���ઔ��"���G@� ��U���@SD^"� ��m� �=u���>�Tdm7G�c����e�{��ݲ��н�������������p����{8&` ���ɣ}��"��k��>��O��`�R��=������T��)I�{� Vu=+�8� ���e~ݡ�x{�� W' ��VeW�e���*�� 3SW��/�����7��b��dՍG��8�p��Q{aS�� G��5Ի����a���2�n �L�F� kݞ��%ȳ���wF�j�'� … b8e5309826 xmp.id:8e729241-8da9-49fe-94d3-308c2fc39be3 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign 15.1 (Macintosh) / 2020-08-14T13:31:51-04:00 xmp.iid:74c999ff-bfe8-47f2-9796-c075cca7c179 xmp.did:c84d9a47-cce7-496e-b770-c8b8e5309826 xmp.did:c84d9a47-cce7-496e-b770-c8b8e5309826 default application/pdf Adobe PDF Library 15.0 False endstream endobj 1140 0 obj >stream 8 endstream endobj 1141 0 obj >stream ����Adobed��� … :0af2d449-4aeb-4214-9828-3c7fa99ed598 uuid:ff6f756d-7e5f-4975-a1dd-ae3bba4c938c application/pdf Meghan Alizabeth Mullaney Adobe PDF Library 20.6.66 endstream endobj 29 0 obj >stream h�,���0 D���`$��S`�:XmV�0�����ӽ;�� xn�I� �3�S;A��J-k�\ٛ�`4϶�C�k�6��&��'1���@tk��3.E�_�����ˑ���O�j&? endstream endobj 30 0 obj >/PageWidthList >>>>>/Resources >/ExtGState >/Font >/ProcSet[/PDF/Text]/Properties >>>/Rotate 0/Tabs/W/Thumb 448 0 R/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>> e … 2020-12-02T15:05:43-05:00 2020-12-02T15:06-05:00 Acrobat PDFMaker 20 for Excel application/pdf Meghan Alizabeth Mullaney uuid:481a330a-5a31-4927-b08d-f4e8dc0eb6a3 uuid:2c65552e-9b9d-4ccc-ad8a-92080034f201 Adobe PDF Library 20.6.66 endstream endobj 35 0 obj >stream h�2�0U0P0�0S�0T�6�4��,͠�9���ҦP�L��Bi3( Qon�cml�}SKSK��F���E� endstream endobj 36 0 obj >/PageWidthList >>>>>/Resources >/ExtGState >/Font >/ProcSet[/PDF/Text]/Properties >>>/Rotate 0/Tabs/W/Thumb 449 0 … 20-12-02T15:06:07-05:00 2020-12-02T15:06:21-05:00 Acrobat PDFMaker 20 for Excel application/pdf Meghan Alizabeth Mullaney uuid:bb07bd45-fd7a-49eb-8490-60fda61ac9a9 uuid:5cb11dad-3cd0-4d23-bace-b0beb0537e31 Adobe PDF Library 20.6.66 endstream endobj 40 0 obj >stream h�2�0W0P0��P�0T�671�̍͡�%����&P����M����lN����ojIbJbI��(;;��)� endstream e
Startup Spotlight: Elastrin Therapeutics Inc. - CURF Skip to content About About CURF Our Team Our Services Technology Transfer Process News Innovators Inventor Resources Glossary of Terms FAQ CURF Maturation Fund Prisma Innovation Maturation Fund Disclose An Invention Forms & Policies Students Student Resources Forms & Policies Graduate Internships Glossary of Terms Industry Industry Resources Partner with CURF Connect with CURF For Startups Available Technology Startups Startup Resources Available Technology Available Technologies All Technologies Advanced Materials Agriculture Aut … rocess News Innovators Inventor Resources Glossary of Terms FAQ CURF Maturation Fund Prisma Innovation Maturation Fund Disclose An Invention Forms & Policies Students Student Resources Forms & Policies Graduate Internships Glossary of Terms Industry Industry Resources Partner with CURF Connect with CURF For Startups Available Technology Startups Startup Resources Available Technology Available Technologies All Technologies Advanced Materials Agriculture Automotive B … n. + Search Available Tech Innovators Ready to disclose your invention to CURF? Submit an Invention Disclosure through the CURF Inventor Portal. + Disclose Your Invention Students Now Accepting Graduate Interns Apply for our internship program at the Clemson University Research Foundation. + Apply Now Industry Search our library of Available Technologies Looking for a technology or invention to commercialize? + Search Available Tech Startups Learn more about how CURF can supp … ifference and impacting the economy where we live. Sign Up Form Email Address * Submit If you are human, leave this field blank. Related Articles Startups , Inventor Success Stories Q&A with Dr. Julian Brinkley February 11, 2025 Innovation , Inventor Spotlight , Startups Clemson Inventors Honored with 2024 InnoVision Awards November 22, 2024 Startups , Inventor Success Stories , Latest News Two Clemson Start-Ups Named 2024 InnoVision Awards Finalists October 9, 2024 Star … tors Resources Frequently Asked Questions Process of Innovation CURF Maturation Fund Industry Industry Resources For Startups Students Student Resources Internship Opportunities Clemson University Research Foundation (864) 656-0797 391 College Avenue, Suite 401 Clemson, SC 29631 facebook twitter linkedin instagram Clemson University Research Foun
Kizoo Portfolio Company Underdog Closes $10M Financing Round - Cyclarity Therapeutics Skip to content Home Our Science Team News & Publications Supplementary Material Investors Contact Us Career Opportunities Home Our Science Team News & Publications Supplementary Material Investors Contact Us Career Opportunities Kizoo Portfolio Company Underdog Closes $10M Financing Round By Cyclarity Therapeutics September 23, 2021 Press Release Mountain View, CA, U.S., September 23, 2021 – Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has close … egin clinical trials in 2023. Mike Kope, Underdog Co-CEO, said: “The ILAP award together with the new funds will enable us to further advance to deliver a simple and affordable preventive therapy for the world”. “We are really into this. This is the first deployment from our $360M commitment to fund the most promising rejuvenation startups through follow-up rounds to advance the therapies from clinical development to public availability”, said Frank Sc … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others. Forever Healthy’s other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world’s cutting-edge medical knowledge, funding research projects on the root causes of aging and hosting the annual Undoing Aging Conference. Further infor
%PDF-1.4 %���� 7629 0 obj > endobj xref 7629 63 0000000016 00000 n 0000004434 00000 n 0000004600 00000 n 0000011834 00000 n 0000012440 00000 n 0000012492 00000 n 0000012543 00000 n 0000012633 00000 n 0000013086 00000 n 0000013595 00000 n 0000013720 00000 n 0000015049 00000 n 0000016201 00000 n 0000017412 00000 n 0000018968 00000 n 0000020638 00000 n 0000021270 00000 n 0000021719 00000 n 0000021885 00000 n 0000021973 00000 n 0000022549 00000 n 0000022938 00000 n 0000023431 00000 n 0000025025 00000 n 0000025165 00000 n 0000025611 00000 n 0000025776 00000 n 0000025936 00000 n 0000026338 00000 n 0 … 64fdfe92360 xmp.did:7b7f0ff3-992b-a54b-8376-56d8c2e1981e default converted from application/x-indesign to application/pdf Adobe InDesign 18.0 (Windows) / 2022-11-01T15:14:48+01:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 25 0 obj > endobj 26 0 obj >stream H��W[o�6~ �� �/:Z���������H�v�K@��#T5������� Y��[��� @(~�#��w.�.�Ŵ�rM�Ŵ(U�虔����w��2�D�g����pd��F��(ŘA�q�0 |��ac۶pha�H ۑ��1_���ѕ,����`�3o��b˚�睹�rb�(�,l[���Բ�t�J�l�ѐ �Je^�\�F�����i�cM�� {5� … WQ*�Q�����`�1T} ��� endstream endobj 27 0 obj > endobj 28 0 obj >stream application/pdf 02Fichier 3 2018-10-09T19:39:08+02:00 2018-10-09T19:39:08+02:00 2018-10-09T19:39:08+02:00 Adobe Illustrator CC 22.0 (Macintosh) uuid:ba4d06ae-64b0-6044-a734-da6765464d54 xmp.did:820aac66-9f3c-b64c-a55c-4ced09d4b566 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:913a27c0-985b-ed45-be00-6626704ff09b xmp.did:0980117407206811822A897E387FE54C uuid:5D20892493BFDB11914A8590D31508C8 … 822A897E387FE54C uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf converted from application/pdf to <unknown> saved xmp.iid:D27F11740720681191099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:0 … DDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-0
GVLtoday - South Carolina Research Authority - SCRA’s SC... Facebook Log In GVLtoday's Post GVLtoday May 4, 2022 · Shared with Public South Carolina Research Authority - SCRA’s SC Launch, Inc. (a nonprofit investment program) has invested $300,000 in Simpsonville-based Elastrin Therapeutics Inc. This investment will advance the biotech startup’s development of therapeutics that restore hardened arteries, decalcify heart valves, and treat diabetes + COPD. scra.org SC Launch, Inc. Announces Investment in Elastrin Therapeutics - SCRA: South Carolina Research Authority All reactions: 2 Like C
Elastrin Therapeutics - Advisory Team | The Org Platform Enrich Pricing Log in Sign up Elastrin Therapeutics Teams Advisory Team Unverified Advisory Team 8 people · 0 jobs The Advisory Team at Elastrin Therapeutics consists of seasoned experts who provide strategic guidance and high-level insights to shape the company's research and development efforts. Leveraging their extensive experience in biotechnology, cardiovascular health, and regulatory affairs, team members help steer clinical programs and enhance the company's overall mission to innovate therapies aimed at reversing card
RESI Boston Sponsors Offer Insight & Highlight Innovation | Next Phase Newsletter Life Science Nation Next Phase Newsletter Search Next Phase Newsletter Home Hot Mandates Previous Issues Podcast Subscribe RESI Boston Sponsors Offer Insight & Highlight Innovation 15 Sep By Candice He , Vice President of Business Development, Global Investment Strategist, LSN The RESI community is built up of powerful players and innovators in the early-stage life science and healthcare arena, and Life Science Nation (LSN) welcomes them back to an in-person RESI next week at the Westin Copley Place … ation Challenge – Winners Announced Hot Longevity Mandate: Europe Based Venture Fund Recent Posts RESI San Diego 2026 Program Guide Released Meet RESI Gold Sponsor RSM: Supporting Life Science Companies Through Growth and Transformation Building Investor Readiness: Watch the First Two Sessions and Join the Final Webinar Hot Investor Mandate: Life Sciences Platform Invests Up to $20M in Early-Stage Therapeutics, Diagnostics, and Medical Technologies Hot Investor Mandate: … offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […] LSN Twitter Tweets by LSciNation Follow Next Phase Newsletter on WordPress.com Contact us +1 (617) 600-0668 [email protected] Archives Archives Select Month June 2026 (17) May 2026 (26)
o2h life - We’re delighted to feature 𝗞𝗲𝘆𝘀𝘁𝗼𝗻𝗲... Facebook Log In o2h life's Post o2h life February 11 · Shared with Public We’re delighted to feature 𝗞𝗲𝘆𝘀𝘁𝗼𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 as our next 𝗼𝟮𝗵 𝗞𝗶𝗰𝗸𝘀𝘁𝗮𝗿𝘁𝗲𝗿 𝗔𝘄𝗮𝗿𝗱 𝘄𝗶𝗻𝗻𝗲𝗿! Many congratulations to 𝗘𝗹𝗲𝗻𝗮 𝗕𝗿𝗶𝗻 and the whole team. As part of this award, Keystone Therapeutics will gain access to o2h Discovery’s specialist drug discovery support tailored for emerging biotech companies. Keystone Therapeutics uses its proprietary tissue-targeting technology to develop safe and effective precis … s.com/ Don’t miss out on Elena’s insightful feedback on winning the Kickstarter Award - check it out in the creative below. At o2h Discovery, we are proud to support Keystone Therapeutics in their efforts to advance innovative therapeutic solutions for challenging cancers, with the aim of improving human health and making a positive impact worldwide. 𝗧𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗲𝗱𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗼𝟮𝗵 𝗞𝗶𝗰𝗸𝘀𝘁𝗮𝗿𝘁𝗲𝗿 𝗶𝗻 𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮 𝗶𝘀 𝗹𝗶𝘃𝗲. If you’re a … s://o2hdiscovery.co/o2h-kickstarter-north-america.../ About the o2h Kickstarter Award: Launched in August 2022, the o2h Kickstarter Award empowers early-stage biotech startups with a chemistry boost for their NCEs, small molecules, and complex drug discovery projects. With over 7+ successful editions, we’ve proudly supported 35+ innovative biotech startups worldwide, accelerating novel drug development programs that have the potential to impact human health and the environmen … impact human health and the environment. To know more about the o2h Kickstarter Award, visit: https://o2hdiscovery.co/o2h-kickstarter-north-america/ Stay tuned, more inspiring winners will be announced soon! #o2hDiscovery #BiotechInnovation #o2hKickstarter #USA #EarlyStageBiotech #SeedingNewIdeas #Award #DrugDiscovery #Winner #PrecisionMedicine #Oncology #SolidCancers All reactions: 1 Like Comment
LSX Congress USA 2026 | Life Science Partnering & Investment You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Executive Partnering Congress Sept 23-24, Forums Sept 22, 2026 BCEC, Boston, USA Home home Agenda expand_more Day 0 Day 1 Day 2 Speak … SA Home home Agenda expand_more Day 0 Day 1 Day 2 Speakers Showcase expand_more Apply Showcase Agenda Investor Feedback Panel Investors expand_more Investor Criteria Syndication Drinks 2025 Investor Attendees Partnering expand_more PartneringONE Partnering Upgrades Networking expand_more Speed Networking Investor Syndication Drinks Sponsor & Partner expand_more Partner With Us Sponsors Partners Sponsorship Brochure More expand_more Plan Your Visit Floorplan Toolkit Sustai … icals Curt LaBelle Managing Partner & Head, AXA IM Global Health Investment Fund BNP Paribas Asset Management Jessica Federer Board Member Angelini Ventures Kiran Reddy Senior Managing Director Blackstone Life Sciences Jennifer Schranz SVP Global Head of Rare Diseases Ipsen Tomoko Hanadate Head of R&D Alliances, Business Development Astellas Pharma Inc. Brian Goodman Managing Director Vida Ventures Debra Yu COO & Partner Panacea Capital Bernard Cooney Partner Casd … ficer Harbour BioMed Fei Shen Head of BD&L USA Boehringer Ingelheim Venture Fund Mary Schaheen President Prevail Partners Scott Miller Executive Director, Alliance and Innovation Management Eli Lilly Renee Aguiar-Lucander Chief Executive Officer Hansa Biopharma Scott DeWire Corporate SVP & Head of Global Business Development Boehringer Ingelheim Mankit Law Senior Director – BD, Search & Evaluation GSK Carla Bauer Director, Oncology S&E, BD&L Merck See All
166 Longevity Unleashed 2 — From Hype to Habits LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and … hen they choose and pay for a program. Payers still need competitive reasons to fund long-horizon prevention. 5) Biology spotlight: elastin & calcification After ~30, elastin assembly wanes → injury–inflammation–calcification cycle. New approaches (e.g., PGG targeting elastin; tropo-elastin scaffolds ) show clinical-stage promise for aneurysms and scar-free healing—implying vascular aging may be partially reversible. 6) Wearables → insights → action HRV and sleep scores h … chael Mann, MHA 164 Longevity, Unleashed: What It Is, What It Isn’t, and How We Fund the Future, Show 1, Part 1 Sep 9, 2025 164 Longevity, Unleashed: What It Is, What It Isn’t, and How We Fund the Future, Show 1, Part 1 Planetary Health First • Mars Next convened a fiery, idea-dense roundtable on healthspan and longevity—spanning… 7 The Power of Pull-Ups: Enhancing Longevity for Planetary Health First.... Aug 10, 2025 The Power of Pull-Ups: Enhancing Longevity for Planetary H
%PDF-1.7 %���� 1684 0 obj > endobj xref 1684 188 0000000016 00000 n 0000006950 00000 n 0000007085 00000 n 0000009277 00000 n 0000009812 00000 n 0000010251 00000 n 0000010551 00000 n 0000010920 00000 n 0000011403 00000 n 0000011442 00000 n 0000011557 00000 n 0000012033 00000 n 0000012621 00000 n 0000012746 00000 n 0000013017 00000 n 0000013277 00000 n 0000013532 00000 n 0000014099 00000 n 0000020492 00000 n 0000028254 00000 n 0000036047 00000 n 0000036172 00000 n 0000036287 00000 n 0000036413 00000 n 0000043328 00000 n 0000051231 00000 n 0000058939 00000 n 0000065978 00000 n 0000074356 00000 n … ��,���� )Ԑ���s�ɗ��6����cW�dp�64Q��%���rlC6������[��OU��zxw=rچC����?t� >stream application/pdf LSN Logo 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 2022-08-30T13:41:09-04:00 Adobe Illustrator 26.3 (Windows) uuid:4f5ba327-632d-4d3e-9750-3dbb5ac53375 xmp.did:08a59ab9-3855-0341-99ff-96f16744b3b7 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:b8b627b9-63dc-f348-9625-1ed948e71f30 xmp.did:b8b627b9-63dc-f348-9625-1ed948e71f30 uuid:5D20892493BFDB11914A8590D31508C8 d … Adobe PDF library 16.07 endstream endobj 1723 0 obj > endobj 1724 0 obj >stream application/postscript POLSINELLI-TAGLINE (Kelly Ludwig) 2023-12-11T09:48:12-06:00 2023-12-11T09:48:12-06:00 2023-12-11T09:48:12-06:00 Adobe Illustrator 28.0 (Macintosh) xmp.iid:b17b322d-6435-4a3e-a4ae-5611e5ee8738 xmp.did:04150ed5-a00d-4602-a0dc-3bf2c2dce1dc uuid:5D20892493BFDB11914A8590D31508C8 default xmp.iid:8977f143-08ef-46b7-9cc6-fd85c3913a9e xmp.did:273aad7b-7c2c-4234-9706-4fb26a471748 uuid … 1 2023-12-08T08:59:07-06:00 Adobe Illustrator 28.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:273aad7b-7c2c-4234-9706-4fb26a471748 2023-12-10T16:10:51-06:00 Adobe Illustrator 28.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator s … 00000 0.003100 0.003100 endstream endobj 1725 0 obj > endobj 1726 0 obj >stream application/pdf RESI Global 2025-08-11T15:19:37-04:00 2025-08-11T15:19:37-04:00 2025-08-11T15:19:37-04:00 Adobe Illustrator 29.4 (Windows) uuid:a7a8c2f4-ed61-49fe-90cd-09bca9c4c51d xmp.did:fe4887cc-ebf3-b940-a98c-c8f65c30ee46 uuid:5D20892493BFDB11914A8590D31508C8 proo
Frontiers | Future treatments for the arteriopathy of ectopic calcification disorders Frontiers in Drug Discovery About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee policy Services Societies National consortia Institutional partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Career opportunities Contact us Al … office Sustainability Career opportunities Contact us All journals All articles Submit your research Search Frontiers in Drug Discovery Sections Sections Anti-Cancer Drugs Anti-Infective Agents Anti-inflammatory and Immunomodulating Agents Cardiovascular and Hematologic Drugs Dermatologic Drugs In silico Methods and Artificial Intelligence for Drug Discovery Neurological Drugs Technologies and Strategies to Enable Drug Discovery Articles Research Topics Editorial board About … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee p … partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Career opportunities Contact us All journals All articles Submit your research Frontiers in Drug Discovery Sections Sections Anti-Cancer Drugs Anti-Infective Agents Anti-inflammatory and Immunomodulating Agents Cardiovascular and Hematologic Drugs Dermatologic Drugs In silico Methods and Artificial Intelligence for Drug Discovery Neurological Drugs Technologies an … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office Frontiers in Drug Discovery Sections Sections Anti-Cancer Drugs Anti-Infective Agents Anti-inflammatory and Immunomodulating Agents Cardiovascular a
Elastrin Therapeutics named winner of 2021 InnoVision Award for Technology Development - SCbio Skip to content Download the 2026 Economic Impact Report About About SCbio Team SCbio Board of Directors SCbio Office Locations Events Calendar Events at a Glance Life + Science Annual Conference BIO International Convention 2026 Drive Demo Day 2026 Sponsorships Membership Membership Benefits Member Login Complimentary Meeting Space Meet Our Members Students Programs Drive Accelerator Available Lab Space Workforce Development Economic Development Advocacy Entrepreneurship News Industry News Share You … ontact Us Search Join Now Elastrin Therapeutics named winner of 2021 InnoVision Award for Technology Development November 12, 2021 Elastrin Therapeutics of Simpsonville, SC has been named winner of the 2021 InnoVision Award for Technology Development , organizers have announced. Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries and tissue by targeting the elastic fiber that makes them work. Founded by
Elastrin Therapeutics - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membe
--> Elastrin Therapeutics Inc. Closes Seed Funding Round with Kizoo Technology Capital top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us All Posts Announcements News Stories Blogs Elastrin Therapeutics Inc. Closes Seed Funding Round with Kizoo Technology Capital Elastrin Therapeutics Mar 5, 2021 3 min read Updated: Apr 3 CLEMSON, S.C. & BERLIN--( BUSINESS WIRE )--Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again. It is the latest addition to the growing … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elevian, LIfT BioSiences, MAIA Biotechnology, Turn.bio, and others. Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging, and hosting the annual Undoing
--> Invest in Cardiovascular Biotech | Elastrin Therapeutics top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Request Investor Deck Built for Institutional Scale Elastrin operates at the intersection of longevity, cardiovascular medicine, and platform biotechnology, creating opportunities for strategic and financial partnerships across multiple indications and markets. Request Investor Deck The Opportunity Solving an Unmet Need One Platform Addressing the mechanism across multiple indications Zero Approved drug therapies that reverse it 300M+ Pe
--> News & Media | Elastrin Therapeutics top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Media Center All Posts Announcements News Stories Blogs Elastrin Presents at MedTech Ahead 2025 Elastrin Presents at MedTech - Elastrin made a strong impression at MedTech Ahead 2025 by presenting its latest advancements in medical technology. Elastin: The rubber band of life You may recognize elastin as a key ingredient in youthful skin, but did you know it’s also an essential component of your heart, lungs, and blood vessels? Recent advances in elastin pres
Elastrin Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 24 Feb 2026 Elastrin Therapeutics Startups | Holding Company | 2017 | South Carolina, United States | < 10 | www.elastrin.com Startups | Holding Company | 2017 | South Carolina, United States | < 10 | www.elastrin.com Last update 24 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Cardiovascular Diseases Endocrinology and Metabolic Disease Biological products Monoclonal ant … and molecular level, with additional participation from previous investors R42 Fund and Healthspan Ventures. Reservoir’s unique approach to neurodegeneration was developed by co-founders Aaron Friedman and Vlad Senatorov, PhD neuroscientists from UC Berkeley who focus on understanding how aging blood vessels effect brain health. The company aims to develop the first drug that specifically targets vascular disease as a new way to restore brain health during natural aging and … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity, Revel Pharmaceuticals, Elastrin Therapeutics, MoglingBio, and others. For more information, please visit: www.kizoo.com Media Contact for Kizoo Frank SchuelerManaging DirectorKizoo Technology [email protected] Media Contact for Reservoir Neuroscience Aaron FriedmanCEO Reservoir [email protected] 08 Nov 2023 · www.globenewswi … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity Therapeutics, Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences and others. For more information, please visit: About Mogling Bio Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by incr … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Elastrin Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Elastrin Therapeutics Elastrin Therapeutics Inc. is a biotech startup dedicated to rejuvenating cardiovascular diseases by developing innovative therapies that target the root causes of cardiovascular conditions. The company aims to provide new hope for patients and their families through cutting-edge research and collaborative partnerships. Industries biopharma biotechnology therapeutics Nr. of Employees small (1-50) Elastrin Therapeutics 200 Patewood Dr
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
--> About Elastrin Therapeutics | Leadership & Mission top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Overcoming a Fundamental Constraint in Human Health A team of passionate individuals on a mission to achieve healthy longevity. Team Leadership Mission Develop therapies that reverse vascular calcification to restore arterial elasticity and eliminate the burden of cardiovascular disease. Vision A world where longevity is defined by resilience across the human lifespan, not by stiffness, vascular failure, and loss of blood flow. … that act where they are needed, not everywhere at once. 03 Institutional rigor: apply standards that meet or exceed expectations of top-tier academic and industry partners. 04 Platform thinking: systems that can scale across indications, partners, and geographies. Our Leadership Shyam Parekh, Ph.D., MBA Chief Executive Officer Shyam Parekh, Ph.D., MBA Chief Executive Officer Experienced leader with decades in corporate strategy, business development, line management, scientif … siness advisor for NIH/VA C3i Program, oversight committee member for Biolocity Fund, and founder of growth advisory consulting firm Read Bio Read Bio Prof. Narendra Vyavahare, Ph.D. Co-Founder & Chief Scientific Officer Prof. Narendra Vyavahare, Ph.D. Founder & Chief Scientific Officer Co-founder of four biotech companies: 1 commercial, 1 in clinical trials, 2 in pre-clinical Hunter Endowed Chair & Professor of Bioengineering at Clemson University; Director of … euroscience) and an MD. Board-certified General Surgeon; completing specialized fellowship in Vascular Surgery at Prisma Health. Authored multiple publications, research spans molecular signaling, breast cancer therapy, and COVID-19-related thromboembolic events Read Bio Read Bio Gerhard Hager, Ph.D. Founder NCD Co. Consulting Expert Gerhard Hager, Ph.D. Founder NCD Co. Consulting Expert Non-clinical development expert with extensive experience in design and ma
--> The Science of Reversing Arterial Calcification | Elastrin top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Where Vascular Biology Meets Engineering. Elastrin’s work is grounded in decades of research across elastin biology, vascular inflammation, nanotechnology, and translational medicine. Elastrin addresses the structural breakdown that defines aging, cardiovascular failure, and loss of biological resilience. Bridging The Therapeutic GAP Attacking the Problem at the Root. Explore Delivery Platform Cardiovascular disease and age-related dec
SC Launch, Inc. Announces $300,000 Elastrin Therapeutics Investment - SCbio Skip to content Download the 2026 Economic Impact Report About About SCbio Team SCbio Board of Directors SCbio Office Locations Events Calendar Events at a Glance Life + Science Annual Conference BIO International Convention 2026 Drive Demo Day 2026 Sponsorships Membership Membership Benefits Member Login Complimentary Meeting Space Meet Our Members Students Programs Drive Accelerator Available Lab Space Workforce Development Economic Development Advocacy Entrepreneurship News Industry News Share Your Company News 2026 … n became an SCRA Member Company in 2018 and received a $25,000 Academic Startup Grant. It also received a $50,000 Federal Matching Grant in 2019. Elastrin became an SC Launch Inc. Portfolio Company in 2022 when it received this first investment of $300,000. It also received a $50,000 grant during SCRA’s pandemic funding round for startups providing Covid-19 solutions. Elastrin recently closed a $10 million funding round, which included this investment. It also recently announ
--> The Science of Reversing Arterial Calcification | Elastrin top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Where Vascular Biology Meets Engineering. Elastrin’s work is grounded in decades of research across elastin biology, vascular inflammation, nanotechnology, and translational medicine. Elastrin addresses the structural breakdown that defines aging, cardiovascular failure, and loss of biological resilience. Bridging The Therapeutic GAP Attacking the Problem at the Root. Explore Delivery Platform Cardiovascular disease and age-related dec
Elastrin Therapeutics | Lifespan Research Institute Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan Alliance
--> Antibody-Targeted Nanoparticle Therapy | Flexibzumab, Elastrin top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Continue Reading The Elastrin Platform Elastrin uses antibody-guided nanoparticles as a biological navigation system. Each particle is programmed to seek damaged elastin and deliver therapy exactly where calcification begins. Continue Reading Enabler Therapy Calcification blocks the procedures that could save patients. Elastrin Clears the Path. Many device interventions for vascular disease cannot be performed when vessel wall … hysicians, and Partners A defined pathway from preclinical evidence to clinical application. Surgical and device interventions for vascular disease are frequently prevented or compromised by the very calcification they are meant to treat. When vessels are too stiff, procedures cannot be performed , leaving patients with no option but radical surgery or, in the case of peripheral artery disease, amputation. Elastrin's approach addresses this
--> Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us All Posts Announcements News Stories Blogs Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round Elastrin Therapeutics Apr 7, 2022 3 min read Updated: Apr 3 Funding used to boost development and start clinical trials in humans in 2023 Greenville, SC, U.S, April 7, 2022 – Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcifi … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others. Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging, and hosting the annual Undoing Aging Conference. For more infor
--> Reverse Arterial Calcification | Elastrin Therapeutics top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Reverse Hardening of the Arteries for Healthy Longevity We’re entering an era where the causes instead of symptoms of diseases are treated. Precision medicine combined with bioengineering can reverse the process of disease formation at the root. At Elastrin Therapeutics we’re already there. Request Investor Deck Explore Technology As we age, arteries stiffen due to calcification. It is a primary driver of he
--> Reverse Arterial Calcification | Elastrin Therapeutics top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us Reverse Hardening of the Arteries for Healthy Longevity We’re entering an era where the causes instead of symptoms of diseases are treated. Precision medicine combined with bioengineering can reverse the process of disease formation at the root. At Elastrin Therapeutics we’re already there. Request Investor Deck Explore Technology As we age, arteries stiffen due to calcification. It is a primary driver of he
Speakers announced for Rejuvenation Startup Summit 2024 - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies
Recognizing Clemson Spinouts from Innovative Research - CURF Skip to content About About CURF Our Team Our Services Technology Transfer Process News Innovators Inventor Resources Glossary of Terms FAQ CURF Maturation Fund Prisma Innovation Maturation Fund Disclose An Invention Forms & Policies Students Student Resources Forms & Policies Graduate Internships Glossary of Terms Industry Industry Resources Partner with CURF Connect with CURF For Startups Available Technology Startups Startup Resources Available Technology Available Technologies All Technologies Advanced Materials Agricul … rocess News Innovators Inventor Resources Glossary of Terms FAQ CURF Maturation Fund Prisma Innovation Maturation Fund Disclose An Invention Forms & Policies Students Student Resources Forms & Policies Graduate Internships Glossary of Terms Industry Industry Resources Partner with CURF Connect with CURF For Startups Available Technology Startups Startup Resources Available Technology Available Technologies All Technologies Advanced Materials Agriculture Automotive B … n. + Search Available Tech Innovators Ready to disclose your invention to CURF? Submit an Invention Disclosure through the CURF Inventor Portal. + Disclose Your Invention Students Now Accepting Graduate Interns Apply for our internship program at the Clemson University Research Foundation. + Apply Now Industry Search our library of Available Technologies Looking for a technology or invention to commercialize? + Search Available Tech Startups Learn more about how CURF can supp … nal Entrepreneurship Competition and the 2021 InnoVision Technology Development award. Elastrin received recognition from BioPharma on its 101 Top BioPharma Startups & Companies in the U.S. Elastrin was named a semifinalist for the NEXT Venture Summit and secured seed funding from Kizoo Technology Capital. The company also received grant funding from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) and the South Carolina Research Au … was named one of three finalists for the 2020 InnoVision Technology Development Award, received a $300 k Phase I NIH SBIR to develop prosthetic joint infection sensors, and has a sublicensee on spine aspects who received a Phase I SBIR funding. Latest News from CURF Stay up-to-date with the latest trends in the innovation and research industry. S
%PDF-1.7 %���� 1 0 obj >/Metadata 1907 0 R/ViewerPreferences 1908 0 R>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 5 0 R/Group >/Tabs/S/StructParents 0>> endobj 5 0 obj > stream x��]Ms�ȑ�+B����n��������2G {�����#�#�9���ߺ���ت�,��x@Ɇ��LQ�Ff"�ˬ��ē�_n?��y=��4z���u����� ��j?��Y�=[�=[T��'f�!!�����&տVy��'� �DJ�q���f�H����_�@�馩}�i�������z�}�~�V����bu�.WѺY�1�Z?�V�/���jC���5 �5�7�w��O���K���g��U;������k���O��_#}���/뜿���[�����翮�3z���^���gJ5ӭ�1�8-�Yqe ����3&��鵖�Z���������o���ׅ1k
SCbio - Congratulations to SCBIO investors & #lifescience... Facebook Log In SCbio's Post SCbio August 29, 2022 · Shared with Public Congratulations to SCBIO investors & #lifescience startup companies Elastrin Therapeutics Inc. and Zylö Therapeutics who have been selected as semifinalists for the NEXT Venture Summit! http://ow.ly/Gncc50KunJH NEXT - Greenville/Upstate SC #sclifesciences #biotech #startup upstatebusinessjournal.com 2022 NEXT Venture Summit semifinalists announced - UPSTATE BUSINESS JOURNAL All reactions: 5 Like Comment
Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round April 7, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, a … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Underdog, Revel Pharmaceuticals, Elastrin Therapeutics, and others. Forever Healthy's other initiatives include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, funding research projects on the root causes of aging, and hosting the annual Undoing Aging Conference. For more information, pl … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
SEC FORM D The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001. FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00 1. Issuer's Identity CIK (Filer ID Number) Previ … ces Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate … ot Applicable 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(4) Section 3(c)(12) Section 3(c)(5) Section 3(c)(13) Section 3(c)(6) Section 3(c)(14) Sec … more than one year? Yes X No 9. Type(s) of Securities Offered (select all that apply) Equity Pooled Investment Fund Interests X Debt Tenant-in-Common Securities X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) 10. Business Combination Transaction Is this offering being made in connection with a business combination transaction … tate/Province/Country ZIP/Postal Code State(s) of Solicitation (select all that apply) Check “All States” or check individual States All States Foreign/non-US 13. Offering and Sales Amounts Total Offering Amount $ 500,000 USD or Indefinite Total Amount Sold $ 50,000 USD Total Remaining to be Sold $ 450,000 USD or Indefinite Clarification of Respo
Elastrin - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investmen … eries A Developer of autologous cell therapies $125M Khosla Ventures , Humboldt Fund & 7 others 65/100 8th Edgewise Therapeutics 2017 , Boulder ( United States ) , Public Developer of therapeutics for skeletal and cardiac muscle diseases $145M Viking Global Investors , Novo Holdings & 12 others 64/100 9th Horizon Therapeutics 2008 , Dublin ( Ireland ) , Acquired Developer of drugs for treating rare and autoimmune diseases $61.8M Quaker Partners Management , Athyrium C … ss 7 funding rounds to date. The company's 1st funding round was a $ ***** Grant (prize money) round , raised on Nov 16, 2018 . Where does Elastrin rank among its competitors? Elastrin ranks 73rd amongst 363 active competitors , of which 108 are funded. It stands 11 th in terms of total funding among its competitors. The most recent competitors to raise funding was Vor Biopharma , which secured $150M in Dec, 2025 . Explore our recently published companies 1Sttrust - Unit
%PDF-1.7 %���� 3827 0 obj > endobj xref 3827 27 0000000016 00000 n 0000005718 00000 n 0000005853 00000 n 0000006899 00000 n 0000007546 00000 n 0000007585 00000 n 0000007698 00000 n 0000007957 00000 n 0000008635 00000 n 0000009058 00000 n 0000009173 00000 n 0000009724 00000 n 0000009988 00000 n 0000010597 00000 n 0000010724 00000 n 0000011502 00000 n 0000011759 00000 n 0000012420 00000 n 0000015071 00000 n 0000028821 00000 n 0000042185 00000 n 0000054376 00000 n 0000060017 00000 n 0000060058 00000 n 0000060135 00000 n 0000066810 00000 n 0000000836 00000 n trailer ]/Prev 21410314>> startxref 0 % … -ac5660fdb530 xmp.did:E0EAC20CB1BCE511889DDE5F03167222 proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign CC 2014 (Windows) / 2017-01-12T18:49:18+01:00 saved xmp.iid:2322c236-896a-ab4c-987f-e5512f89dff5 2017-05-03T11:58:21-07:00 Adobe Illustrator CC 2017 (Windows) / application/pdf report_cover Adobe PDF library 15.00 False 1 True False 630.000000 810.000000 Pixels Cyan Magenta Yellow Black Default Swatch Group 0 R=0 G=0 B=0 1 CMYK PROCESS 74.60 … T3?�����E{�5�ݓ� ��Ǹ ����#��O�GF� T, �Y&���KԌ�D� x�2v > endobj 4 0 obj >stream application/pdf CalXlogos 2017-05-01T15:19:54-07:00 2017-05-01T15:19:54-07:00 2017-05-01T15:19:23-07:00 Adobe Illustrator CC 2017 (Macintosh) uuid:b388a6e0-17ac-d74a-9f3d-84c750c7a06b xmp.did:04165177-5a19-4385-b557-32b9da607def uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590D31508C … ��5����?�߿��ф��%�~3�d��� q��z�H�P���R �#�h����#��@�,�/!7�����-sM�,x\ RFP�����>�����7�g��@�p)2�#��\ֹ������SR��~����NQ�����.����e��7ޜ1;��փ�@S�Q'�~���؞ �R�b�����!�� U�e����z�X|��L�Y�7Iur���X>�S�[���B���;���g�!{l�я�>���Uf�͠q{=j�~a���_�_�/P%Q�|C��+d�J�K���W �� |j*H���O�K$ny _>m5M�|8��=�v4zʁIT����!��b>��!@4�9 ���������{�zM� �;��#�������Jt��c�ԟgJ� ��O��&�HN�f����km;y�0�d�c`l��� R�RnH�r �'���Nj�V'����= I�3�b�H� �(�W*#\l�y�� N�jCf��� … �yw�����7н�.���P���i�~!S�{I�=���8�/��L��� �.q�q��C4`��2 � P' ����V��\ RFp)�U2&3o�&�Xu�lm:9M ���t�W�s�9Nj��h��m��w}@!�m��q N�,;� qE�3���D�Z|����z��nM�5�!��s{O���čf�T��=*��6t5Ϻ Ĩ�o(,�Jjb�[ nF�֤Ԟ��d����.ˊ츠���!n>R��Ԟ��ǡDǕ�R������L�30�LU\D�E[O&Kk}U���r>����;r7�'s�� J՞���k���E�t�#8������R�x� F}�&굦s걮-mF^��5g��V��(m�^��W6ҏ�
Discovering the Nature of Long… ‑ Taste Life Nutrition Podcast ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 22 juillet 2024 1 h 2 min Discovering the Nature of Longevity: What is the Elastic of Life Taste Life Nutrition Podcast Lire In this episode of Taste Life Nutrition Radio & Podcast, we had the pleasure of hosting Douglas Mulhall, a trailblazer in global health innovation and the co-founder of Elastrin Therapeutics. We explored the fascinating world of elastin and its critical role in maintaining our body’s flexibility and overall health. Highlights from the e
Elastin Could Revolutionize Aneurysm, Cardiovascular & Skin Treatments– Douglas Mulhall EP 335 - audio | Health Declassified Episode on Amazon Music Home Home Podcasts Podcasts Library Cancel Sign in Elastin Could Revolutionize Aneurysm, Cardiovascular & Skin Treatments– Douglas Mulhall EP 335 - audio Health Declassified Nov 12 2024 • 45 mins What is the Elastic of Life? We're thrilled to welcome Douglas Mulhall, journalist, author, award-winning documentary filmmaker, and co-founder of Elastrin Therapeutics. Douglas shares the latest developments in elastin research and its pote
--> #1 Bestseller features Elastrin scientist’s discoveries & inventions top of page Company Science Platform Investors Media Center Menu Contact Us Menu Contact Us All Posts Announcements News Stories Blogs #1 Bestseller features Elastrin scientist’s discoveries & inventions Elastrin Therapeutics Jul 21, 2025 1 min read May 2024 - #1 Amazon bestseller status has been awarded to an Elastrin co-founder's book Discovering the Nature of Longevity: Restoring the heart and body by targeting hidden stress . Douglas Mulhall's book is the first to reveal for a general audience the my
Douglas Mulhall - Author of Di… - The Bioinventors Podcast - Apple 팟캐스트 검색 홈 신규 인기 차트 검색 2024년 10월 19일 36분 Douglas Mulhall - Author of Discovering the Nature of Longevity and Co-founder of Elastrin Therapeutics: The power of Elastin The Bioinventors Podcast 재생 Send us Fan Mail In this episode of Biotech LifeStream , we welcome Douglas Mulhall, a pioneering author and researcher whose groundbreaking work on longevity reshapes how we think about heart and body health. His book, Discovering the Nature of Longevity: Restoring the Heart and Body by Targeting Hidden Stress , features a foreword by C
Elastrin limbers up for success with Kizoo funding boost Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeutics doses fir... AnHor … research (and opinions)? Harness’ two-pronged Parkinson’s program secures MJFF grant Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy Perplexity enters the consumer health AI arena Startup targets ‘untreatable blindness’ with bionic eye system Science Corp lands $230m to commercialize vision restoration chip MUSCLE: FLT’s revolutionary AI-powered supplement for strength and longevity Ergothioneine: The little-known molecule tra
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
LSX Europe 2024 Attendees | Life Science Executives You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Fundraising & Investment 7-8 April 2027 - Main days, Lyon, France 6 April 2027 - Pre-day forums (Life Science Companies only) Home home Biotec … rs Investor Asahi Kasei Pharma Corporation Director / Management Ascension Life Fund Investor Ascension Life Fund Investor Askel Healthcare C-Level / Founder / Chairman Askel Healthcare C-Level / Founder / Chairman Askel Healthcare C-Level / Founder / Chairman Association of British HealthTech Industries Director / Management Astellas Director / Management Astellas Investor Astellas Pharma SVP / VP / Head Astellas Pharma Europe Investor Astellas Pharma Europe Ltd SVP / VP / H … d Boehringer Ingelheim Pharma GmbH SVP / VP / Head Boehringer Ingelheim Venture Fund GmbH Investor Boehringer Ingelheim Venture Fund GmbH Investor Boost Capital Partners Investor Bootstrap Europe Investor Boston Scientific SVP / VP / Head Boston Scientific Director / Management Boyds SVP / VP / Head Brain Stimulation C-Level / Founder / Chairman Brain Stimulation C-Level / Founder / Chairman Brainomix Limited C-Level / Founder / Chairman Brainomix Ltd C-Level / Founder / Chai … ment Calliditas Therapeutics US Inc C-Level / Founder / Chairman Calyx Ventures Fund Investor Cambridge Consultants Other Cambridge Enterprise Director / Management Cambridge Innovation Capital Investor Cambridge Innovation Capital Investor Cancer Research Horizons Investor Cancer Research Horizons Investor Cancer Research Horizons Investor Capital Enterprise SVP / VP / Head Capital Enterprise Investor Capital Family Office Investor Capricorn Partners Investor Cardiac Impact … evel / Founder / Chairman Cizzle Biotech C-Level / Founder / Chairman Clarendon Fund Managers Investor Claret Capital Partners Investor Claret Capital Partners Investor Claret Capital Partners Investor Claret Capital Partners Other Claris Ventures Investor Claris Ventures Investor Claris Ventures Investor Clarity for Action Ltd Director / Managem
LiveLung - Thank you to AstraZeneca and BioNTech for... Facebook Log In LiveLung's Post LiveLung April 14 · Shared with Public Thank you to AstraZeneca and BioNTech for showcasing at our #SCLCSummit26 and for your partnership as industry leaders. Your support helps bring together science, creativity, and community - highlighting the progress, innovation, and hope within the #SCLC space! All reactions: 29 1 comment 2 shares Like Comment Most relevant Top fan Jeff Stibelman Two amazing companies with vast knowledge, information and resources to help change the narrative for so many. I’ve do